文献速递临床试验与 GCP流行病学与生物统计

模型化剂量探索临床试验设计中协变量的纳入问题

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs.
PubMed 文献 · Stat Med · 2025-01-01

该研究基于一项真实试验,评估在I期模型化剂量探索研究中纳入或忽略患者协变量对个体目标剂量推荐和患者安全的影响。研究发现,忽略预后协变量会导致正确选择比例大幅降低和过量用药增加;而纳入协变量可改善操作特性,但有时会轻微降低正确选择比例并增加过量用药。为此,作者提出使用贝叶斯Lasso贝叶斯逻辑回归模型(BLRM)和Spike-and-Slab BLRM,发现这两种方法在考虑变量纳入方面平均更合适。

要点

  • 忽略预后协变量会导致正确选择比例大幅降低和过量用药增加。
  • 纳入协变量可改善操作特性,但有时会轻微降低正确选择比例并增加过量用药。
  • 贝叶斯Lasso BLRM和Spike-and-Slab BLRM在考虑变量纳入方面平均更合适。

核心结论

  • 对于连续和二元协变量,忽略预后协变量会导致正确选择比例大幅降低和过量用药增加;纳入协变量可改善操作特性但有时会轻微降低正确选择比例并增加过量用药;BLRM结合贝叶斯Lasso或Spike-and-Slab平均更适合考虑变量纳入。

研究设计与样本

  • 基于一项真实试验,评估在I期模型化剂量探索研究中纳入或忽略患者协变量对个体目标剂量推荐和患者安全的影响,并研究了几种变量惩罚标准。

主要发现

  • 对于连续和二元协变量,忽略预后协变量导致正确选择比例大幅降低和过量用药增加。
  • 纳入协变量在所有情景下可带来良好操作特性,但有时会轻微降低正确选择比例并增加过量用药。
  • BLRM结合贝叶斯Lasso和Spike-and-Slab BLRM平均更适合考虑变量纳入。

关键数值与推荐

  • 对于连续和二元协变量,忽略预后协变量导致正确选择比例大幅降低和过量用药增加。
  • 纳入协变量可带来良好操作特性,但有时会轻微降低正确选择比例并增加过量用药。
  • BLRM结合贝叶斯Lasso和Spike-and-Slab BLRM平均更适合考虑变量纳入。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a growing number of Phase I dose-finding studies that use a model-based approach, such as the CRM or the EWOC method to estimate the dose-toxicity relationship. It is common to assume that all patients will have similar toxicity risk given the dose regardless of patients' individual characteristics. In many trials, however, some patients' covariates (e.g., a concomitant drug assigned by a clinician) might have an impact on the dose-toxicity relationship. In this work, motivated by a real trial, we evaluate an impact of taking into account (or omitting) some patients' covariates on the individual target dose recommendations and patients' safety in Phase I model-based dose-finding study. We investigate several variable penalisation criteria and found that, for continuous and binary covariates, omitting a prognostic covariate leads to a drastically low proportion of correct selections and an increase of overdosing. At the same time, including a covariate can lead to good operating characteristics in all scenarios but can sometimes slightly decrease the proportion of good selections and increase the overdosing. To tackle this, we propose to use a Bayesian Lasso Bayesian Logistic Regression Model (BLRM) and Spike-and-Slab BLRM. We have found that the BLRM coupled to the Bayesian LASSO and the BLRM with Spike-and-Slab are on average better appropriate to consider variable inclusion.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Ollier A, Mozgunov P. On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs. Stat Med. 2025. PMID: 39853785. doi:10.1002/sim.10337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。